Method of T Lymphocyte Generation From Hematopoietic Stem Cells

University Reference Number: U-4710
Web Published: Mar 30, 2011

Summary:  This technology includes methods for the production of T lymphocytes  and  Cytotoxic (Natural Killer, or NK) lymphocytes from uncommitted hematopoietic stem/progenitor cells. It begins with undifferentiated hematopoetic stem cells, cultured under conditions which promote specification of the lymphocyte lineage. These cells subsequently progress through the developmental steps, resulting in selective expansion of a repertoire of immune cells restricted to recognition of foreign antigens, and expressing functional receptors for recognition of a wide array of such foreign antigens.  These methods provide the potential for intervention to select against immunologic specificities associated with autoimmunity and graft-versus-host disease (GVHD).

Market Applications:  Current technologies for engineering the immune system have largely relied on expansion of pre-existing mature T cells with specificity against a desired target, or introducing a specific T cell receptor into expanded mature T cells. These approaches do not address the need to regulate the immune response in a prospective manner, and to generate a broad range of immune specificities while prohibiting the development of alloreactive clones.  This technology offers the potential to produce a functional immune system from a sample of the patient's own bone marrow or from induced pluripotent stem cells derived from patient fibroblasts.   

Features, Benefit & Advantages:
T lymphocytes and NK cells with non-specific recognition of a wide array of foreign antigens can be generated using this approach.

The T lymphocytes can be engineered to select against immunologic specificities that may eventually lead to autoimmunity, GVHD, or graft rejection.

Intellectual Property Status: Patent pending. This technology is part of an active and ongoing research program.  Opportunities exist for developmental research support/licensing under either exclusive or non-exclusive terms.

Patent Information:
Licensing Contact:
Beth Drees
Director of Business & Technology Development
University of Utah
Gerald Spangrude
Birgitta Mitchell
Stem Cells
Non-Cancer Disease Therapeutics
Cancer Diagnostics and Treatment